Website designed by: Vanmala VONGKINGKEO
Icons made by Twitter from www.flaticon.com
NEWS
CARDIATEAM consortium meeting March 2025
This year’s CARDIATEAM’s consortium meeting was hosted by our partner SIB on their premises in Lausanne. The one and a half days of meeting were filled with the presentation of preliminary results and exiting scientific discussions!
Review on animal model for DCM published!
The CARDIATEAM consortium is shedding light on diabetic cardiomyopathy (DCM), a heart condition linked to Type 2 Diabetes (T2DM). This review from the CARDIATEAM consortium emphasizes the complexity of DCM and the importance of considering various factors like diet, lifestyle, and genetics in research. By refining experimental models, the team aims to better understand DCM and find new ways to diagnose and treat it. This research is a crucial step towards personalized medicine and better heart health outcomes. Read our full publication here: https://academic.oup.com/cardiovascres/article/119/5/1130/6694799?login=false
CARDIATEAM's summary of achievements at the end of period 5
By the end of period 5 which ended February 2024, CARDIATEAM consortium has successfully focused its recruitment efforts on two main groups of volunteers (no heart failure with and without type 2 diabetes [T2DM]) to enroll a total number of 894 patients. To ease the recruitment a fourth amendment to the protocol has been implemented in all sites, one Dutch centre (Amsterdam) has been reactivated and some centres (FIBHGM and Mondor’s hospitals & UNIVDUN) agreed to raise their foreseen numbers of recruited patients.
The required infrastructure to collect imaging data
and the CARDIATEAM web-based database platform are fully operational with successful
implementation of all data flows and quality assurance measures. The database has
been structured to gather all clinical, imaging and omics data of the recruited
patients.
After a successful quality check to LIH and a preliminary
clustering analysis based on S.O.M methodology, biological samples have been
selected for the first omics analyses early P5. Thanks to the synergic work of WP2,
WP3 and WP4, we have performed two additional descriptive analyses on available
data (N=550 included patients in November 2023 and N= 637 patients in February 2024)
to document the distribution characteristics of patients compatible with eligibility
criteria. These descriptive analyses comforted the one performed during RP4 on a
total of 406 participants with T2DM and without T2DM patients, and paving the way
for a first cluster analysis.
Upon receiving the samples from IBBL, UNITO and
HMGU engaged in meticulous experimental preparations that included the selection
of the most suitable kits and the randomization of samples to mitigate potential
confounding factors. This attention combined with stringent quality control measures,
ensured the reliability of the generated OMICs data.
To fulfil the objectives to perform an initial unsupervised
analysis on available -omics data produced by WP5 and available in the CARDIATEAM
database (WP4), a synergic work of WP4, WP5 and WP6 was organized with bi-monthly
meetings. The initial -omics data from WP5 and available in this period were from
genetics (SNP), methylomics, proteomics, targeted metabolomics and targeted lipidomics
data generated from 164 patient samples. Work was performed in collaboration with
the groups generating the data (WP5: UNITO, HMGU) to prepare the data for
subsequent analysis (e.g. quality control, normalisation, outliers, imputation).
Following the first clustering of patients with specific clinical variables (WP4),
the first step was to investigate potential patterns in the different omics data,
in an unsupervised way across methylomics, proteomics and targeted lipidomics
and metabolomics. Multi-omics integration produced latent variables, or global spaces
of common variation, which correlated to different levels to clinical variables,
allowing to identify different potential signature for phenotypes related to diabetic
cardiomyopathy. In the future we will use these signatures to investigate enriched
pathways and potential mechanisms underlying the pathology.
Important Milestone for our CARDIATEAM study
We are thrilled to inform you that CARDIATEAM reached an important milestone during the summer months:
Our study recruited its 1000th patient at the beginning of June 2024 !! 
Prolongation of CARDIATEAM project
We are happy to announce to you that CARDIATEAM has been granted an extension of 24
months. This gives us the possibility to catch up with delays of recruitment of
our CARDIATEAM study caused mainly by the impact of the COVID-19 pandemic and to
reach the objectives of our project.
The new ending date of CARDIATEAM project is now February 2026
Summerschool on metabolic disorders and vulnerability with CARDIATEAM speakers
CARDIATEAM will be represented at this summer school which is organised by the Medical Faculty of the the University of Paris-Est Creteil with several speakers from our consortium. Focused on Metabolic disorders & vulnerability as a Public Health issue, this summer school will discuss transdisciplinary approaches to vulnerability on metabolism, public health policies, and environmental risks.
Expert researchers in the field will give talks and encourage scientific exchange through discussion, Nobel Prize Laureate Elizabeth Blackborn (Physiology 2009) will be participating with a keynote speech.
When? September 22nd 2023
Where? at Maison du Handball, 1 Rue Daniel Costantini, 94000 Créteil, France
Free participation but mandatory to register. Please register here: https://forms.office.com/e/1dFfqvZTLN
You can find the complete program here: https://eurlive.u-pec.fr/en/news/events/eur-live-summer-school-2023-metabolic-disorders-vulnerability-a-public-health-issue-
CARDIATEAM publishable summary period 1-4
The fourth period (P4) still suffered from the effects of the COVID-19 pandemic impacting the recruitment rate of the CARDIATEAM study. However, by the end of P4, WP2 has achieved in collaboration with WP3, WP4 and WP5, the implementation of an adapted study protocol in all participating countries. The accuracy/integrity of the collected data and a harmonious conduction of the study throughout the recruiting sites was ensured by the global monitoring .
The main achievement of P4 was the opening of all the 16 centers in all countries involved in the study. P4 ended with a total of 578 patients recruited and 1st and 2cd year follow-up have been performed for the first recruits.
The required infrastructure to collect imaging data in the CARDIATEAM cohort has been installed. The CARDIATEAM web-based database platform is operational and has been successfully validated. Participating centres are being trained and certified by transferring collected data to the imaging core labs and uploading the measurements to a central repository. All data flows are in place and quality assurance measures have been implemented. Hereto, a certification process has been put in place as well as continuous monitoring of the core-lab performance. As the rate of patient inclusion has increased in P4 (total recruitment has more than doubled during RP4 i.e.; RP3 n=250 while by the end of RP4 n=578) the data-flow to and from the web-platform are put to the test, and modifications and further improvements were implemented on the go, based on the feedback of imaging core-labs and imaging centers.
The database which will gather all clinical, imaging and omics data of the recruited patients has been set up and structured. We have developed an eCRF system to collect clinical data from recruited patients. This system contains functionality allowing the manual, expert review of registered data to avoid errors and missing data. Training sessions for clinical research assistants on the tool have been organised at each of the different sites. A data transfer protocol has been implemented between the main data processing partners to securely push validated records into the central database. Pipelines for processing of clinical data into the database have been established and web-based mining tools to query the content of the database to allow live monitoring of collected data have been developed.
Like in previous periods, sample collection kits have been distributed to the already recruiting centers the collected biological samples has been sent for a successful quality check to LIH, and some of them have been selected by WP4 for the omics analyses to be started early RP5. The unsupervised machine learning methodology required to analyze the future deep phenotypic data has been set-up, tested and used to analyze the 408 initial volunteers for a preliminary clustering analysis identifying four clusters of patients based on S.O.M methodology to start early in P5. The synergic work of WP2, WP3, WP4 and WP5 thus has led to the identification of patients with outstanding clinical, imaging and routine biological phenotyping that will be undergo multi-OMICs analysis in early RP5 .
Concerning animal models, WP7 partners have now finalised the overview of existing preclinical models of metabolic disorders pertinent to the project and published a first joint review article. Another article will be submitted early in RP5. Two models of interest have been selected for the use within the consortium and a joint protocol across 6 partner’s lab bases on mice issued from the same provider are being finalized early RP5.
CARDIATEAM's first consortium publication is out !
We are proud to share the Cardiateam’s first consortium article on experimental models of Diabetic CardioMyopathy (DCM) : “Diabetic cardiomyopathy: the need for adjusting experimental models to meet clinical reality “ published in Cardiovascular Research, Volume 119, Issue 5, May 2023, Pages 1130–1145. In this review article we identify the current limitations of rodent models and discuss how future mechanistic and preclinical studies should integrate key confounding factors to better mimic the DCM phenotype. The article is free of access: https://doi.org/10.1093/cvr/cvac152 Have a read!
CARDIATEAM on LinkedIn
We have set up a page on LinkedIn! Make sure to follow us in order to stay updated on our project!
CARDIATEAM consortium meeting took place on 23rd to 24th March 2023 in Madrid
Hybrid meetings- Hybrid group photos! CARDIATEAM had its consortium meeting on 23-24th March, hosted by CIBER in Madrid! Lots of existing discussions on first preliminary results.
CARDIATEAM in person consortium meeting took place on 26th August 2022 in Barcelona
After two years of online meetings we finally had the pleasure to meet again in person this August on the occasion of the annual conference of the European Society of Cardiology. CARDIATEAM organised a short consortium meeting on the premises of the congress which allowed us to discuss and plan upcoming challenges.
All present members of CARDIATEAM enjoyed seeing each other again and are looking forward to our next meeting which will also be hold in presence in Madrid, next March.
Publishable summary Period 1- Period 3
The third period (P3) of CARDIATEAM continued with the effects and sanitary measures of the COVID-19 pandemic impacting on the recruitment rate of the CARDIATEAM study. However, by the end of P3, WP2 has achieved in collaboration with WP3, WP4 and WP5, the implementation and adaptation of the study protocol and all related documents in all participating countries. To ensure the accuracy/integrity of the collected data and a harmonious conduction of the study throughout the recruiting sites, a global monitoring has been implemented.
The main achievement for the P3 has been to open centers in all countries involved in the study. Eleven sites have been initiated and other sites initiation visits are planned before summer 2022. P3 ended with a total of 250 patients recruited and first year follow-up have been performed for the first recruits.
The required infrastructure to collect imaging data in the CARDIATEAM cohort has been installed. The CARDIATEAM web-based database platform is operational and has been successfully validated. Participating centres are being trained and certified by transferring collected data to the imaging core labs and uploading the measurements to a central repository. All data flows are in place and quality assurance measures have been implemented. Hereto, a certification process has been put in place as well as continuous monitoring of the core-lab performance. As the rate of patient inclusion has increased in P3, the data-flow to and from the web-platform are put to the test, and modifications and further improvements were implemented on the go, based on the feedback of imaging core-labs and imaging centers.
The database which will collect all clinical, imaging and omics data of the recruited patients has been set up and structured. We have developed an eCRF system to collect clinical data from recruited patients. This system contains functionality allowing the manual, expert review of registered data to avoid errors and missing data. Training sessions for clinical research assistants on the tool have been organised at each of the different sites. A data transfer protocol has been implemented between the main data processing partners to securely push validated records into the central database. Pipelines for processing of clinical data into the database have been established and web-based mining tools to query the content of the database to allow live monitoring of collected data have been developed. The unsupervised machine learning methodology required to analyze the future deep phenotypic data has been set-up and tested.
Like in previous periods, sample collection kits have been distributed to the already recruiting centers As biological sample collection suffers from the delay in patient’s recruitment (see above), the analyses on the omics measurement have not started yet however a first batch of samples has been sent for a successful quality check to LIH .
Concerning animal models, WP7 partners have now finalised the overview of existing preclinical models of metabolic disorders pertinent to the project and submitted a first joint publication. Two models of interest have been selected for the use within the consortium and a join protocol is being finalized to start mid-RP4.
First CARDIATEAM Scientific Exchange Meeting organised
The CARDIATEAM consortium organised with the help of Prof Giuseppe Matullo from Partner 12, the University of Turino, its first Scientific Exchange Meeting on 22nd of April 2021.
The topic of this first Scientific Exchange in a virtual format (due to the ongoing pandemic situation) was on “Omics investigation in the frame of the CARDIATEAM consortium”. The talks were given by the members of the CARDIATEAM consortium on the latest results on the use of omics in the cardiovascular field:
1. Giuseppe Matullo form Partner 12 University of Turin (Italy) : Introduction to genomics and epigenomics investigations in cardiometabolic diseases
2. Flora Sam from Partner 21 Lilly (USA): The transcriptome in cardiometabolic phenotypes – insights for diabetic cardiomyopathy and heart failure?
3. Rui Wang-Sattler from Partner 13 Helmholtz Forschungszentrum (Germany): Identification and validation of candidate biomarkers of metabolic diseases (pre-diabetes, T2D, MI, CKD) by metabolomics.
The talks were then followed by fruitful discussions on the use of Omics to deep-phenotype the patients recruited prospectively in the CARDIATEAM clinical study of the project.
The Omic strategies will be part of the topics discussed during the upcoming Scientific Advisory Board meeting scheduled in the 2nd of July 2021.
First patient in CARDIATEAM study enrolled
Our CARDIATEAM study was initially thought to start in March 2020 but had then been hit as the rest of the world by the COVID pandemic and its measures which were particularly affecting all clinical activities, impacting on the start of our study.
We now have the immense pleasure to announce that on Friday 2nd of October 2020 we were able to include our first patient for the CARDIATEAM study! The patient has been recruited at the Mondor APHP Hospital in Creteil and went through all scheduled exams.
The other participating recruitment centers have already scheduled patient visits in the coming weeks, so the study is officially kicked off now.
CARDIATEAM webinar for imaging
With the aim to instruct the teams of the clinical centers who will participate to the CARDIATEAM study, a webinar had been organised at the end of November 2019.
Prof Genevieve DERUMEAUX (Inserm), Prof. Javier BERMEJO (CIBER) , Prof Alban REDHEUIL (APHP) and Prof. Jan D’HOOGE (KU Leuven) gave lectures on the different imaging aspects of the study.
Consortium meeting: 2-3 April 2020! - POSTPONED
Due to the COVID -19 situation the project decided to postpone to a later date the consortium meeting that had been scheduled originally to take place on 2nd and 3rd of April 2020, hosted by CIBER in Madrid.
CARDIATEAM Kick-off Meeting, March 2019
The first CARDIATEAM project meeting took place in March 2019!
This first gathering was an important and exciting milestone: the beginning of our innovative project about diabetic cardiomyopathy.
All the members of our consortium are eager to collaborate and work on an innovative approach to assess whether Type 2 Diabetes has an influence on the development of diabetic cardiomyopathy and if it is unique and distinct from the other types of heart failure.
Acknowledgement
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 821508.
See more on Cordis portal.
The contents of this website and the view expressed in the news and publications are the sole responsibility of the authors and under no circumstances can be regarded as reflecting the position of the European Union.
Read our privacy policy and legal notice.